| 2026-08-04 | 10-Q | 10.3 | Employment Agreement, dated March 11, 2026, by and between the Registrant and Brian Stephenson. |
|---|
| 2026-06-10 | 8-K | 10.2 | 2026 Employee Stock Purchase Plan |
|---|
| 2026-06-10 | 8-K | 10.1 | 2026 Equity Incentive Plan and Forms of Stock Option Grant Notice, Stock Option Agreement, Restricted Stock Unit Grant Notice and Restricted Stock Unit Grant Agreement thereunder |
|---|
| 2026-05-15 | 10-Q | 10.2 | Sensei Biotherapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy. |
|---|
| 2026-05-15 | 10-Q | 10.1 | Sensei Biotherapeutics, Inc. Severance and Change in Control Plan. |
|---|
| 2026-03-30 | 10-K | 10.25 | Retention Agreement, dated as of December 22, 2025, entered into with Josiah Craver. |
|---|
| 2026-03-30 | 10-K | 10.24 | Retention Agreement, dated as of December 22, 2025, entered into with Christopher Gerry. |
|---|
| 2026-03-30 | 10-K | 10.23 | Letter Agreement dated as of January 29, 2026, between Millennium Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited and Faeth Therapeutics, Inc. |
|---|
| 2026-03-30 | 10-K | 10.22 | Letter Agreement, dated as of May 15, 2023, between Millennium Pharmaceuticals, Inc. and Faeth Therapeutics, Inc. |
|---|
| 2026-03-30 | 10-K | 10.21 | Amended and Restated TAK-228 Asset Purchase Agreement, dated as of May 15, 2023, between Faeth Therapeutics, Inc. (as successor in interest to Calithera Biosciences, Inc.) and Millennium Pharmaceuticals, Inc. |
|---|
| 2026-03-30 | 10-K | 10.20 | License Agreement, dated as of March 18, 2019, between Faeth Therapeutics, Inc. (as successor in interest to Petra Pharma Corporation and Ravenna Pharmaceuticals, Inc.) and Takeda Pharmaceutical Company Limited. |
|---|
| 2026-03-30 | 10-K | 10.19 | Exclusive License Agreement, dated as of August 10, 2007, between Faeth Therapeutics, Inc. (as successor in interest to Calithera Biosciences, Inc., Millennium Pharmaceuticals, Inc. and Intellikine, Inc.) and The Regents of the University of California and acting through its Office of Technology Management, University of California San Francisco, as amended by Amendment No. 1 dated as of March 13, 2009, Amendment No. 2 dated as of July 8, 2009, Amendment No. 3 dated as of November 30, 2010, Amendment No. 4 dated September 8, 2014, Amendment No. 5 dated August 4, 2021, and Amendment No. 6 dated as of February 1, 2022. |
|---|
| 2026-03-30 | 10-K | 10.15 | Amended Retention Agreement, dated as of February 17, 2025, entered into with Josiah Craver. |
|---|
| 2026-03-30 | 10-K | 10.14 | Lease Agreement, by and between Sensei Biotherapeutics, Inc. and RREF II 451D, LLC, dated as of January 13, 2021 (incorporated by reference to Exhibit 10.14 to the Registrant’s Annual Report on Form 10-K (File No. 001-39980) filed with the SEC on March 15, 2022). |
|---|
| 2026-03-30 | 10-K | 10.10 | Employment Agreement, dated July 31, 2024, by and between the Registrant and Christopher Gerry |
|---|
| 2026-03-30 | 10-K | 10.6 | Faeth Therapeutics, Inc. 2019 Stock Incentive Plan and forms of agreements thereunder. |
|---|
| 2026-02-18 | 8-K | 10.4 | Form of Stock Option Grant Notice and Stock Option Agreement for Inducement Grants Outside of the Sensei Biotherapeutics, Inc. 2021 Equity Incentive Plan |
|---|
| 2026-02-18 | 8-K | 10.3 | Employment Letter between the Company and Anand Parikh, effective February 17, 2026 |
|---|
| 2026-02-18 | 8-K | 10.2 | Form of Registration Rights Agreement, by and among Sensei Biotherapeutics, Inc. and certain investors signatory thereto |
|---|
| 2026-02-18 | 8-K | 10.1 | Form of Securities Purchase Agreement, dated as of February 17, 2026, by and among Sensei Biotherapeutics, Inc. and each investor listed on Exhibit A thereto |
|---|
| 2025-11-14 | 10-Q | 10.1 | Form of Consulting Agreement, dated November 14, 2025, entered into with John Celebi, Edward van der Horst and Stephanie Krebs. |
|---|
| 2024-11-14 | 10-Q | 10.1 | Employment Agreement, by and between Sensei Biotherapeutics, Inc. and Josiah Craver, dated as of July 12, 2024. |
|---|
| 2024-05-09 | 10-Q | 10.4 | Amendment No. 1 to Services Agreement, by and between Sensei Biotherapeutics, Inc. and Monomy Advisors, LLC, dated May 7, 2024. |
|---|
| 2024-05-09 | 10-Q | 10.2 | Consulting Agreement, by and between Sensei Biotherapeutics, Inc. and Erin Colgan, dated as of April 11, 2024. |
|---|
| 2024-05-09 | 10-Q | 10.1 | Amended and Restated Non-Employee Director Compensation Policy |
|---|
| 2024-02-29 | 10-K | 10.10 | Employment Agreement, dated October 19, 2023, by and between the Registrant and Stephanie Krebs. |
|---|
| 2023-05-23 | 8-K | 10.1 | Purchase Agreement, dated May 23, 2023, by and among Sensei Biotherapeutics, Inc., on the one hand, and Apeiron Investment Group Ltd., Presight Sensei Co-Invest Fund, L.P., Presight Sensei Co-Invest Management, L.L.C., Christian Angermayer, Apeiron SICAV Ltd. - Presight Capital Fund ONE, and Altarius Asset Management Ltd., on the other hand. |
|---|
| 2023-05-01 | 10-K/A | 10.7 | Amended and Restated Non-Employee Director Compensation Policy. |
|---|
| 2023-03-29 | 10-K | 10.13 | Consulting Agreement, by and between Sensei Biotherapeutics, Inc. and Doctor Hope LLC, dated as of December 7, 2022. |
|---|
| 2023-03-29 | 10-K | 10.12 | Non-Employee Director Compensation Policy (incorporated by reference to Exhibit 10.12 to the Registrant’s Annual Report on Form 10-K (File No. 001-39980) filed with the SEC on March 15, 2022). |
|---|
| 2023-03-29 | 10-K | 10.11 | Amended and Restated Employment Agreement, dated December 7, 2022, by and between the Registrant and Edward van der Horst. |
|---|
| 2022-08-09 | 10-Q | 10.1 | Employment Agreement, dated May 5, 2022, by and between the Registrant and Patrick Gallagher. |
|---|
| 2022-03-15 | 10-K | 10.16 | Amended and Restated Employment Agreement dated January 1, 2022, by and between the Company and Erin Colgan |
|---|
| 2022-03-15 | 10-K | 10.16 | PDF COURTESY COPY |
|---|
| 2022-03-15 | 10-K | 10.14 | Boston Lease |
|---|
| 2022-03-15 | 10-K | 10.14 | PDF COURTESY COPY |
|---|
| 2022-03-15 | 10-K | 10.13 | Separation from Employment Letter and Separation Agreement, by and between Sensei Biotherapeutics, Inc. and Marie-Louise Fjaellskog, dated as of December 1, 2021. |
|---|
| 2022-03-15 | 10-K | 10.13 | PDF COURTESY COPY |
|---|
| 2022-03-15 | 10-K | 10.12 | Non-Employee Director Compensation Policy. |
|---|
| 2022-03-15 | 10-K | 10.10 | Amended and Restated Employment Agreement, by and between Sensei Biotherapeutics, Inc. and Robert H. Pierce, dated as of January 28, 2021 (incorporated by reference to Exhibit 10.14 to the Registrant’s Registration Statement on Form S-1 (File No. 333-252138)). |
|---|
| 2021-05-03 | 8-K | 10.1 | First Amended and Restated Employment Agreement, dated April 28, 2021, by and between the Company and Erin Colgan. |
|---|
| 2021-03-30 | 10-K | 10.12 | Non-Employee Director Compensation Policy. |
|---|